Theatreworks continuing touring Shakespeare tradition uccs.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from uccs.edu Daily Mail and Mail on Sunday newspapers.
UCL and AstraZeneca collaborate on immuno-oncology research
Search jobs UCL and AstraZeneca collaborate on immuno-oncology research
Researchers from the UCL Division of Infection & Immunity will lead on two collaborative projects with AstraZeneca. The projects’ long-term aim is to contribute to the development of new cancer treatments.
These research collaborations will investigate immune checkpoints which are key biochemical pathways that regulate our body’s immune responses. These are important in a number of conditions, including cancer and autoimmune diseases.
Immune checkpoints carry out the important role of keeping our immune response at normal levels, and therefore not harming healthy cells. However, they can also ‘block’ specialist cells within our immune system from attacking and destroying cancer cells.
AstraZeneca and UCL to collaborate on two immuno-oncology projects
4th February 2021
British drugmaker and researchers from the UCL Division of Infection & Immunity will collaborate on two projects which will aim to contribute to the development of new cancer treatments.
The new research collaborations will investigate immune checkpoints – key biochemical pathways that regulate the body’s immune responses.
Although immune checkpoints help to keep the body’s immune response at normal levels by not harming healthy cells, they can also block specialist immune cells from attacking and destroying cancer cells.
Over the last decade, the emergence of checkpoint inhibitor drugs have revolutionised cancer treatment and demonstrated benefit in clinical results for patients with solid tumours.